|
|
|||||||||||||||||||||||||||||
Alexion Pharmaceuticals, Inc. Buyback
OLI recorded this information on 12/15/2014
Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercializes two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. Co. also has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
Open the ALXN Page at The Online Investor (in a new window) »
|
|